Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 26 May

Paulina Peters
May 26, 2022

Morning Bell 25 May

Paulina Peters
May 25, 2022

Morning Bell 24 May

Sophia Mavridis
May 24, 2022

Morning Bell 23 May

Sophia Mavridis
May 23, 2022

Weekly Wrap 20 May

Sophia Mavridis
May 20, 2022

Morning Bell 19 May

Paulina Peters
May 19, 2022

Morning Bell 18 May

Sophia Mavridis
May 18, 2022

Morning Bell 17 May

Sophia Mavridis
May 17, 2022

Morning Bell 16 May

Paulina Peters
May 16, 2022

Weekly Wrap 13 May

Sophia Mavridis
May 13, 2022

Morning Bell 12 May

Paulina Peters
May 12, 2022